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Introduction
Endothelins (ETs) are a family of genes, composed of sequences producing three 21 amino acid proteins, including endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3) (1). Endothelins derive from precursor proteins after cleavage by a specific metalloproteinase, endothelin converting enzyme (ECE) (2) . Endothelin-1 (ET-1) is the predominant isoform in the family whereas isoforms ET-2 and ET-3 are less commonly expressed (1) . ET-1 is also the most common circulating form of endothelin and is produced by somatic cells, including endothelial cells, vascular smooth muscle cells as well as many epithelial tumours. Endothelins are able to work in both paracrine and autocrine fashions, by binding to specific cell surface receptors, namely endothelin receptor A (ET A R) and endothelin receptor B (ET B R) (3) . Binding of endothelins to their receptors mediates a number of functions, including vasoconstriction, pain, inflammation and most importantly, cancer (1, 2) . The genes for ET-1, ET-2, ET-3, ET A R and ET B R are located on chromosomes 6, 1, 20, 4 and 13 respectively (4).
Of the two surface receptors for ET-1, ET A R has more affinity for ET-1 and ET-2 than for ET-3, whereas ET B R has equal affinity to all three ET isoforms. ET A R is found on vascular smooth muscle cells while ET B R is expressed on endothelial cells, vascular smooth muscle cells, macrophages and platelets (5) . Also, both receptors are distributed in the kidney, airway smooth muscle cells and pulmonary vessels (6, 7) .
In cancers, there are different expression profiles of the endothelin receptors when compared with normal tissues (Table 1) with ET A R/ET B R expression ratios differ significantly between cancer types. Regarding the expression level of endothelin receptors, cancers are divided into three categories : (1) cancers that express predominantly ET A R such as nasopharyngeal, thyroid, prostate, colon, pancreatic, gastric, renal and breast cancers (8) (9) (10) (11) (12) (13) (14) (15) ; (2) cancers predominately expressing ET B R such as melanoma and brain tumours( glioblastoma and astrocytoma) (16) (17) (18) and (3) cancers which express both ET A R and ET B R such as oral, lung, bladder, vulvar and ovarian cancers (19) (20) (21) (22) (23) .
ET-1 mediates mitogenic effects in a variety of epithelial tumours via ET A R (2) and in non-epithelial tumours such as melanoma by ET B R (24) . ET-1 is a mitogen for lymph vessel endothelial cells via ET B R, so ET B R blockade impairs lymphangiogenesis (25) . Thus, ET B R expression in cancer is associated with lymphatic invasion (26) . Similarly, ET A R overexpression in cancer has been shown to be associated with aggressive biological behaviour (27) . This is reflected in the fact that high ET A R expression is more prevalent in cancers with distant metastasis (8) . The current review is to study the roles of endothelins in human cancer and the potential roles of them in cancer therapy.
The role of stroma in carcinogenesis related to endothelin
Cancer progression depends on the biological characteristics of the malignant cells and their interactions with benign cells and components of the surrounding stroma (28) . Solid tumours are mixture of variety of cells; including cancer cells and cancer-associated cells (fibroblasts, macrophages and endothelial cells). All these cells can overexpress ET-1 and its receptors (29, 30) .
Fibroblasts suppress preneoplastic epithelial proliferation (31) . They are, however, the first cells that are recruited during early carcinogenesis and can be induced to secrete many factors that affect the cancer cells, which can result in increased aggressiveness (32) .
When they accumulate within the cancer area, they are termed cancer-associated fibroblasts (CAFs), becoming recruited by cancer signalling and have different morphological and functional features from their normal counterparts (33) . CAFs have higher proliferative rates and are resistant to apoptosis (34) . CAFs are made up of different cells from various sources and local stromal fibroblasts are the major source (35) . Once recruited, fibroblasts may differentiate to myofibroblasts. This process is called fibroblast to myofibroblast transdifferentiation, and is activated by several growth factors such as transforming growth factors-beta (TGF-ß), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF) which are produced by cancer cells (36, 37) . CAFs have an essential role in head and neck squamous cell carcinoma progression (38) . The presence of myofibroblasts in the tumour stroma is a negative prognostic factor as they increase invasion of cancer cells.
These myofibroblasts have a contractile phenotype and increase the proliferative and migratory capacity in cancer. For example, in oral squamous cell carcinoma (OSCC), the presence of myofibroblasts in the tumour stroma is associated with higher risk of invasion and poor prognosis (39) . The behaviour of CAFs is also modulated in part by endothelins (40) .
In the oral cavity, fibroblasts can amplify the proliferation and migration of cancer cells stimulated by ET-1. In this process, ET-1 stimulates the release of bioactive ligands such as ADAM17 from fibroblasts which bind to epidermal growth factor receptor (EGFR) on cancer cells and then trigger an increase in COX-2 expression (40) . It was shown that in head and neck squamous cell carcinomas (HNSCC), the expression of COX-2 and EGFR correlated with a poor prognosis (41) . These data suggest different mitogenic peptides may contribute to HNSCC progression and this could be evidence for stromal-epithelial interaction (41, 42) . EGFR was also noted to be overexpressed in HNSCC patients in another study (43). Additionally, it was shown that activation of EGFR increases cancer cell migration and invasion due to decreasing cell adhesion (44) .
ET-1 stimulates oral cancer cell invasion via both of its receptors, which are expressed by oral fibroblasts (40, 45) . Oral fibroblast contractile phenotype is mediated primarily by ET B R, however ET-1 stimulates oral fibroblasts to promote invasion of oral cancer cells in a paracrine manner (39).
Endothelin and angiogenesis in cancer
The tumour microenvironment is different from that of normal tissues. An important difference is that within a cancer, most regions are hypoxic (46) . In addition, blood supply in cancer has a different structure from normal vessels (47) . For example, vascular channels in cancer are often lined by cancer cells, mimicking a normal vessel, a state called "mimicry".
Alternatively, vessels may be lined by cancer cells and endothelial cells, which is termed "mosaicism" (48, 49) . Also, cancer blood vessels are highly permeable and prone to leaking (50) . Cancers displaying vasculogenic mimicry proliferate rapidly and are more aggressive with higher risk of metastasis (51, 52) . Hypoxia -inducible factor 1-α (HIF-1α) expression around the cancer cell-lined vessels is common and may show that hypoxia is involved in inducing cancer cell-lined vessel formation (53, 54) . HIF-1α also regulates vascular endothelial growth factor (VEGF) which has been indicated as an enhancer for formation of cancer cell lined vessels in vitro (54) . In oral cancer, HIF-1α expression level was shown to be positively correlated with the aggressiveness of the cancer (55).
ET-1 activates the hypoxia-responsive pathway by inducing stabilization of HIF-1α under normoxic conditions. Then, HIF-1α up-regulates VEGF transcription. HIF-1α and VEGF production can thus be amplified by ET-1 under normoxic or hypoxic conditions (56) .
In cancer cells, ET-1 can itself be up-regulated due to hypoxia. This may lead to a positive feedback system, whereby ET-1 expression stimulated hypoxic pathways which stimulate further ET-1 expression, maintaining constant vascular expansion regardless of oxygen status. This dual role may explain the link between endothelins and cancer aggression.
Endothelin, EMT and metastasis
Epithelial mesenchymal transition (EMT), a cancer hallmark, involves losing epithelial markers such as E-cadherin, and gaining mesenchymal markers, like N-cadherin and vimentin (57) . The blockage of signals and pathways involving in EMT development is critical for reverting EMT and the related biological effects such as drug sensitivity. The ET-1/ ET A R axis is one of these pathways, having several roles in cancer progression and its overexpression correlates with the advanced stages (29, 57, 58) . As part of this association with advanced staging, the ET-1/ ET A R axis has also been implicated in promotion of EMT as well as cell proliferation, angiogenesis, escape from apoptosis, invasion and metastasis (30) . For example, it has been shown that overexpression of ET A R in nasopharyngeal carcinoma initiates tumour cell metastasis (8) .
Low E-cadherin and high vimentin in primary head and neck squamous cell carcinoma was associated with a 100% metastasis rate compared to those primary carcinomas with incomplete EMT markers, which were associated with a metastatic rate of 44% (59) . Also, ET-1 and ET-3 have been found to up-regulate N-cadherin in human melanoma cell lines, a factor which is commonly associated with loss of E-cadherin (3). The observed downregulation of E-cadherin and associated catenin adhesion proteins in melanocytes and melanoma cells are likely connected to the same mechanisms.
In addition to their roles in vasculogenesis, both VEGF and HIF-1α are associated with EMT in some cancers. For example, this phenomenon was observed in cancer cell lines from tongue and hypopharynx (60) . VEGF is also correlated with invasion depth and increased risk of metastasis to lymph nodes in patients with head and neck squamous cell carcinoma (61) . Due to its role in stimulating both VEGF production and HIF-1α stabilization, this places the endothelin axis at a significant control point for advanced tumour characteristics. 
The ET-1 axis in chemo-resistance

Endothelin and Cancer Therapeutics
Since endothelin mediated pathways contribute to cancer growth and progression, The effects of endothelin antagonists in human cancer cell lines have been tested in multiple studies, and a summary of these can be seen in Table 2 . The most commonly used antagonist in such studies is atrasentan. Atrasentan (ABT-627) is an orally bioavailable nonpeptide, small molecule competitive ET inhibitor acting via decreasing the binding affinity of ET A R for ET-1 (81). Atrasentan inhibited cell proliferation and increased apoptosis in nasopharyngeal cancer cell lines (8) . In addition, atrasentan was shown to reduce cell invasion in breast cancer cell lines (70) . In ovarian cell lines, atrasentan was found to increase apoptosis and inhibit cell proliferation and VEGF expression (71) . Furthermore, it was found to lead to cell death in prostatic cancer (73) .
The second most widely used ET inhibitor used in oncology trials is zibotentan (ZD4054), an orally bioavailable ET A R antagonist (63, 74) . It is the only ET antagonist which targets ET A R without decreasing ET B R expression level. Zibotentan has been found to inhibit cell proliferation and tumour growth in human ovarian carcinoma cell lines (7), but not in breast cancer cell lines (75) . In addition, zibotentan was found to revert the EMT phenotype, inhibit invasiveness and restore drug sensitivity in ovarian cancer cells (30) . It reduces angiogenesis and also can reduce ET-1-induced epidermal growth factor receptor (EGFR) transactivation (76) . Zibotentan combined with the anti-mitotic chemotherapy agents paclitaxel or docetaxel enhances apoptosis compared with either agent alone (77).
BQ123 is an ET A R antagonist and BQ788 is selective ET B R antagonist, which are often used in combination. Combination therapy with BQ123 and BQ788 were demonstrated to suppress growth of oral squamous cell carcinoma and oesophageal squamous cell carcinoma (78) . In addition, these drugs in combination blocked the conversion of matrix metalloproteinases to active forms resulting in inhibition of cell invasiveness (79) . On its own, BQ123 was found to inhibit the proliferation of colorectal and lung cancer cell lines (80, 81) .
Bosentan is an endothelin receptor antagonist, which inhibits ET-1 action through a combination of interference with both ET A and ET B receptors (82) . It has been found to induce cell death in human melanoma cell line (83) .
These ET inhibitors have been shown to work on cancers in several animal xenograft models, the results of which are summarised in Table 3 In some cancers, the combination of one endothelin receptor antagonist with an anticancer drug has shown good results as a useful therapeutic strategy. For example, ET B R antagonism can improve the efficacy of paclitaxel on breast cancer in rats (7) . In in vitro studies, using ET A R antagonists such as zibotentan combining with paclitaxel or the DNA crosslinking chemotherapy agent cisplatinum showed an increase in antitumor activity in ovarian cancer (77, 85) . ET-1 may modulate the resistance pathways during treatment with cytotoxic therapies via several mechanisms, though it is likely to be that abrogation of hypoxia is the main factor that can be blocked by ET A R (86).
Despite the promising results in cell lines and animal studies, clinical trials results were disappointing. The bulk of clinical trials to date have taken place in prostate cancer.
The 2 largest studies were based on 809 and 312 patients using atrasentan and zibotentan respectively (87, 88) . In these studies, the treatment with endothelin antagonists showed no improvement in prognosis of patients with prostatic adenocarcinomas. A clinical trial was also performed in which bosentan was used to treat metastatic melanoma. The result of this trial was also disappointing, with only 6 of the 32 patients with the disease being stabilized by the treatment (89). Thus, more clinical trials may be needed for assessing the usefulness of the endothelin based treatments.
Endothelin receptors antagonists used in these trials have been noted to have some side effects. For example, liver toxicity was observed in 2-18% of the patients treated with bosentan (90). The most common side effects with atrasentan therapy were headache, rhinitis, and peripheral oedema (91).
Endothelins and bone formation
ET-1 stimulates new bone formation which can be blocked by ET A R antagonists, but not ET B R antagonists (92) . In the late stage of prostate cancer and breast cancer, osteoblastic activity is stimulated by factors secreted by cancer cells resulting in osteoblastic metastases, leading to the development of drugs targeting this process (93) . A study on prostate cancer cell lines showed that the presence of both ET-1 and an anti-ET-1 antibody blocked osteoclastic bone resorption (94) . Osteoblasts have a high affinity for ET A R and ET-1 (95, 96) . In animal studies, selective ET A R antagonist treatment decreased new bone formation (97, 98) . Additionally, atrasentan prolonged the time to the progression threshold levels of bone alkaline phosphatase; a biomarker of disease progression, by nearly twice compared with placebo in prostate cancer patients (505 days versus 254 days), though it did not reduce overall risk of progression (88).
Correlations with vascular endothelial growth factor
The current anti-angogenesis therapy focus on the action of vascular endothelial growth factor (VEGF). The prognostic and regulartory roles of VEGF have been extensviely studied (99) (100) (101) (102) (103) . In fact, VEGF was shown to collaborate with ET-1 and ET A R in cancer angiogenesis (104) (105) (106) . Combination therapies targeting both VEGF and endothelins may be a potent control of angiogenesis.
Conclusion
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